Sucralfate (sucralfate oral) NDC 55154-4348

NDC codes

FDA NDC Directory

Product NDC (as listed)55154-4348Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55154-4348Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55154-4348-5	55154434805	5 CUP in 1 BAG (55154-4348-5) / 10 mL in 1 CUPMarketed from Oct 31, 2024

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate oral
Active ingredients: Sucralfate — 1 g/10mL
Dosage form: Suspension
Route: Oral
Labeler: Cardinal Health 107, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209356
Marketing start: Oct 31, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 55154-4348_b22f1eca-76df-4fc7-b3e5-2f007a7d94d6SPL ID b22f1eca-76df-4fc7-b3e5-2f007a7d94d6SPL set ID a0c9f585-1007-4996-aef7-e17cd55d28cdRxCUI 313123UNII XX73205DH5UPC 0055154434850
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N455154434805 followed by a unit qualifier and the quantity

Package 55154-4348-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 31, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209356

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209356
Product	Strength	Form · route	Labeler	Product NDC
Sucralfatesucralfate oral	Sucralfate 1 g/10mL	SuspensionOral	AvPAK	50268-745
Sucralfatesucralfate oral	Sucralfate 1 g/10mL	SuspensionOral	Amneal Pharmaceuticals LLC	65162-062
Sucralfatesucralfate oral	Sucralfate 1 g/10mL	SuspensionOral	Precision Dose, Inc.	68094-041
Sucralfatesucralfate oral	Sucralfate 1 g/10mL	SuspensionOral	AvKARE	42291-781